Runben Biotechnology Co Stock

Runben Biotechnology Co EBIT

The EBIT of Runben Biotechnology Co (603193.SS) as of Aug 12, 2026 is 309.31 M CNY. In the previous year, EBIT was 248.39 M CNY — a change of 24.53% (higher).

EBIT

309.31 MCNY

YoY

24.53%

Last updated:

In 2026, Runben Biotechnology Co's EBIT was 309.31 M CNY, a 24.53% increase from the 248.39 M CNY EBIT recorded in the previous year.

The Runben Biotechnology Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M CNY)
Date
EBIT (M CNY)
Jan 1, 2022
179.00 base
Jan 1, 2023
248.39 base
Jan 1, 2024
309.31 base
Jan 1, 2025 (e)
382.25 base
Jan 1, 2026 (e)
461.07 base
Jan 1, 2027 (e)
546.55 base
Jan 1, 2028 (e)
639.85 base
YEAREBIT (M CNY)
2028 est 639.85
2027 est 546.55
2026 est 461.07
2025 est 382.25
2024 309.31
2023 248.39
2022 179.00
Access this data via the Eulerpool API

Runben Biotechnology Co Revenue

Runben Biotechnology Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
856.09 M CNY
179.00 M CNY
160.04 M CNY
Jan 1, 2023
1.03 B CNY
248.39 M CNY
226.03 M CNY
Jan 1, 2024
1.32 B CNY
309.31 M CNY
300.16 M CNY
Jan 1, 2025 (e)
1.55 B CNY
382.25 M CNY
315.58 M CNY
Jan 1, 2026 (e)
1.87 B CNY
461.07 M CNY
378.63 M CNY
Jan 1, 2027 (e)
2.22 B CNY
546.55 M CNY
447.75 M CNY
Jan 1, 2028 (e)
2.60 B CNY
639.85 M CNY
523.03 M CNY

Runben Biotechnology Co Margins

Runben Biotechnology Co stock margins

The Runben Biotechnology Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Runben Biotechnology Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Runben Biotechnology Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
54.06 %
20.91 %
18.69 %
Jan 1, 2023
56.11 %
24.05 %
21.88 %
Jan 1, 2024
58.03 %
23.47 %
22.77 %
Jan 1, 2025 (e)
58.03 %
24.63 %
20.33 %
Jan 1, 2026 (e)
58.03 %
24.63 %
20.22 %
Jan 1, 2027 (e)
58.03 %
24.63 %
20.18 %
Jan 1, 2028 (e)
58.03 %
24.63 %
20.13 %

Runben Biotechnology Co Stock analysis

What does Runben Biotechnology Co do? Runben Biotechnology Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Runben Biotechnology Co's EBIT

Runben Biotechnology Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Runben Biotechnology Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Runben Biotechnology Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Runben Biotechnology Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Runben Biotechnology Co stock

EBIT of Runben Biotechnology Co is 309.31 M CNY in 2026.

EBIT of Runben Biotechnology Co changed from 248.39 M CNY to 309.31 M CNY, representing a 24.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Runben Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Runben Biotechnology Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Runben Biotechnology Co

All Key Metrics — Runben Biotechnology Co